Acino Holding AG's EBIT per Share for the
six
months ended in Dec. 2013 was €-4.34.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2013 was €-4.34.
During the past 12 months, the average EBIT per Share Growth Rate of Acino Holding AG was -334.90% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 14.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Acino Holding AG's EBIT per Share or its related term are showing as below:
FRA:S3H'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -64.4 Med: 6.1 Max: 60.3
Current: 14
During the past 11 years, the highest 3-Year average EBIT per Share Growth Rate of Acino Holding AG was 60.30% per year. The lowest was -64.40% per year. And the median was 6.10% per year.
FRA:S3H's 3-Year EBIT Growth Rate is not ranked
in the Drug Manufacturers industry.
Industry Median: 7.25
vs FRA:S3H: 14.00
The historical data trend for Acino Holding AG's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2013 was €-4.34
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acino Holding AG (FRA:S3H) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Acino Holding AG EBIT per Share Related Terms
Thank you for viewing the detailed overview of Acino Holding AG's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Acino Holding AG is a Switzerland-based company engaged in the pharmaceutical industry. The Company develops, manufactures, and markets pharmaceuticals in novel drug delivery forms internationally. It is divided into four segments Business to Consumer (BtC); Business to Business (BtB); Technology marketing (TM); and Production (Prod). The BtC segment comprises all direct marketing activities. Under the company's "Acino Switzerland" brand and, with the promise of Swiss quality, the company sells its products in emerging markets around the globe. This reporting segment includes the business purchased from Mepha/Cephalon in the Middle East, Africa, Latin America and Asia. The BtB segment comprises Acino's business with its internally developed products, for which the company also owns the intellectual property rights. Acino develops and produces high-quality medicines with proven active ingredients and modern drug delivery systems and grants licenses for them to leading pharmaceutical and generic pharmaceutical companies worldwide. The technology marketing segment comprises a broad spectrum of fully integrated contract services, including procurement, contract development, production and packaging for companies in the life sciences industry. On behalf of these customers, Acino develops a comprehensive product pipeline on the basis of its special technological know-how. This includes both new types of medicines as well as projects with innovative drug delivery systems for established active ingredients. The production segment is responsible for the manufacturing of products and the supplying of the other three segments, and generates turnover through the reimbursement of its services. The manufacturing costs of products are credited to the production segment at standard prices along with remuneration in the form of a mark-up for materials and production costs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:S3H has been successfully added to your 